Immunotoxins: A new approach to cancer therapy

Ellen S. Vitetta, Keith A. Krolick, Muneo Miyama-Inaban, William Cushley, Jonathan W. Uhr

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter presents evidence that conjugates of toxin and antigen can induce specific immunologic unresponsiveness. A potential problem in the repeated administration of immunotoxins in cancer patients is the generation of an antibody response to the injected immunotoxin. The induction of immunologic unresponsiveness to specific antigens would be useful not only in cancer patients that are to receive immunotoxins containing tumor-reactive antibody but also in treating autoimmune diseases. For example, in the case of an autoimmune disease in which the antigen has been identified, it may be possible to delete the B cells responsive to this autoantigen by injecting autoantigen-A chain. Immunotoxins represent a new approach to pharmacology. In considering the use of immunotoxins for treating human cancer, the tumor burden must be a major consideration—at least until the therapeutic index of immunotoxins can be significantly improved. Studies of the metabolic half-life and tissue distribution of immunotoxins are also of a preliminary nature.

Original languageEnglish (US)
Title of host publicationBiotechnology and Biological Frontiers
PublisherTaylor and Francis
Pages73-85
Number of pages13
ISBN (Electronic)9780429705915
ISBN (Print)9780367020460
DOIs
StatePublished - Jan 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Social Sciences(all)

Cite this

Vitetta, E. S., Krolick, K. A., Miyama-Inaban, M., Cushley, W., & Uhr, J. W. (2019). Immunotoxins: A new approach to cancer therapy. In Biotechnology and Biological Frontiers (pp. 73-85). Taylor and Francis. https://doi.org/10.4324/9780429050329-7